The updated NCCN guidelines no longer say that active surveillance is “preferred” for low-risk prostate cancer, prompting some physicians to claim this recommendation may encourage overtreatment and is a “step back” from progress made over the last decade, which has been defined by active surveillance as the preferable care option for most low-risk localized prostate […]
When preparing to treat a patient for osteoporosis, it might be wise to compare leading guidelines because guidelines from two key organizations often don’t agree. The ACP and the National Osteoporosis Foundation (NOF) have come up with guidelines that differ in terms of what therapies, how long to treat, how long between scans, and more. […]
Available from Guideline Central, the free, quick-reference print and digital pocket guide covers the most recent American Society of Clinical Oncology (ASCO) Hepatocellular Carcinoma Guidelines. Accessed by web and offline mobile devices, the pocket guide covers key points, treatment, first- and second-line therapies, a downloadable PDF, and links to other resources in advanced hepatocellular carcinoma.
This is the third edition of the guidelines – the last coming in 2014 – providing a resource and guidance specifically for primary care practitioners about how to plan care for childhood cancer survivors. “A care plan just really encourages coordination, especially if a child has a very complicated post-cancer treatment history with a lot […]
As the influenza season will coincide with the ongoing COVID-19 pandemic, it’s perfect timing for the release of the CDC Advisory Committee on Immunization Practices (ACIP) influenza vaccination updated guidance. The comprehensive report indicates that COVID-19 vaccines can be co-administered with other vaccines, including influenza vaccines like egg-based flu vaccines and cell culture-based inactivated and […]
Bookmark this page – or download the information directly, if you prefer – to ensure you’re always connected to the latest and greatest information on the very best in NSCLC treatment regimens (NCCN Guidelines).
An update from the original ASCO guideline on this topic published in 2012, 60 studies, primarily retrospective, were included in the review. New to this version of the guideline, the Panel offers recommendations on approved doses of immunotherapy and targeted therapies that can be offered to obese patients with cancer.
These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in their decisions about the prevention and treatment of venous thromboembolism (VTE) – a common complication among patients with cancer who are at a markedly increased risk for morbidity and mortality.
These evidence-based guidelines from the American Society of Hematology (ASH), the International Society on Thrombosis and Haemostasis (ISTH), the National Hemophilia Foundation (NHF), and the World Federation of Hemophilia (WFH) are intended to support patients, clinicians, and health care professionals in their decisions about management of von Willebrand Disease (VWD), a common inherited bleeding disorder.
The American Society of Clinical Oncology (ASCO) published a guideline update about the selection of optimal adjuvant chemotherapy regimens and targeted therapy for early breast cancer, namely trastuzumab emtansine. In a second recommendation, the ASCO guideline addressed the use of biosimilar forms of trastuzumab—five of which have been approved by the FDA.